Sign In to Follow Application
View All Documents & Correspondence

Process For The Preparation Of Fluticasone Propionate

Abstract: "PROCESS FOR THE PREPARATION OF FLUTICASONE PROPIONATE" The present disclosure relates to an improved process for the preparation of fluticasone propionate.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
07 February 2014
Publication Number
52/2015
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2019-07-25
Renewal Date

Applicants

MYLAN LABORATORIES LTD
PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500 033

Inventors

1. JADHAV, SAKHARAM
PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500 033
2. BOHARA, CHANDERSINGH
PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500 033
3. WAGH, GHANSHYAM
PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500 033
4. GORE, VINAYAK GOVIND
PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500 033
5. GADAKAR, MAHESHKUMAR
PLOT NO 564/A/22, ROAD NO 92, JUBILEE HILLS, HYDERABAD - 500 033

Specification

.
BACKGROUND OF THE INVENTION

FIELD OF THE DISCLOSURE

The present disclosure relates to an improved process for the preparation of fluticasone propionate.

DESCRIPTION OF THE RELATED ART

Fluticasone propionate is a corticosteroid of the androstane family which has potent anti-inflammatory activities and is widely accepted as a useful therapy for the treatment of inflammatory and allergic conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Fluticasone propionate is chemically named as 6a, 9a-difluoro-17a- (((fluoromethyl) sulfanyl) carbonyl)-11p-hydroxy-16a-methyl-3-oxoandrosta-l,4-dien-17a-yl propionate and is represented by the following chemical structure:
U.S. Patent No. 4,335,121 discloses a process for the preparation of fluticasone propionate, wherein 6a,9a-difluoro-11 p-hydroxy-16a-methyI-3-oxo-l7a-(propionyloxy)androsta-1,4-diene-17p-carboxylic acid of formula IV is treated with dimethylthiocarbamoyl chloride to yield I7p-(N,N(dimethy 1 carbamoyl)thio)carbony I -6a,9a-difluoro-11 p-hydroxy-16a-methy 1 -17a-propiony-loxy-3-oxoandrosta-l,4-diene of formula III. This is hydrolyzed by refluxing in diethyl amine to obtain the thioic acid of formula II. The compound of formula II is then reacted with bromochloromethane in the presence of sodium bicarbonate to give a chloromethylester of formula Ha. The compound of formula Ha is converted to an iodomethylester by halogen exchange, and subsequently treated with silver fluoride to yield the fluticasone propionate of formula I. The reaction steps are illustrated by the following scheme:

SUMMARY OF THE DISCLOSURE

One aspect of the present disclosure is to provide an improved process for the preparation of fluticasone propionate.
In one embodiment, the present disclosure provides an improved process for the preparation of fluticasone propionate comprising the steps of:
a) dissolving fluticasone propionate in a ketone solvent to produce a mixture,
b) heating the mixture slowly for 1-2 hours to get a clear solution,
c) adding water to the step (b) solution at 50-60°C,
d) cooling to -5°C to 10°C, and
e) isolating fluticasone propionate.

In another embodiment, the present disclosure provides an improved process for the preparation of fluticasone propionate having a particle size less than 400 microns.

In other embodiments of the present disclosure, the obtained fluticasone propionate particles are used for formulating pharmaceutical compositions.

DETAILED DESCRIPTION OF THE DISCLOSURE

It is to be understood that the description of the present invention has been simplified to illustrate elements that are relevant for a clear understanding of the invention, while eliminating, for purposes of clarity, other elements that may be well known.

More specifically, the present disclosure relates to an improved process for the preparation of fluticasone propionate.

One embodiment of the present disclosure is to provide an improved process for the preparation of fluticasone propionate comprising the steps of:

a) dissolving fluticasone propionate in a ketone solvent to produce a mixture,
b) heating the mixture slowly for 1 -2 hours to get a clear solution,
c) adding water to the step (b) solution at 50-60°C,
d) cooling to -5°C to 10°C, and
e) isolating fluticasone propionate.

According to the present disclosure, fluticasone propionate is dissolved in a ketone solvent at 25-30°C. The temperature of the solution is raised to 50-60°C and water is added to the above solution slowly at 50-60°C over the period of 1 -2 hours to get the precipitation. The precipitated mixture is cooled to -5°C to 10°C and stirred for I hour. The obtained solid is filtered and washed with a ketone solvent/water mixture. The compound is dried under the vacuum to get crystalline fluticasone propionate in desired particle size.

Within the context of the present disclosure, the ketone solvent employed above may include, but is not limited to, acetone, butanone, methyl isobutyl ketone, methyl ethyl ketone, methyl tertiary butyl ketone, and mixtures thereof. Again, one of skill in the art will recognize numerous additional ketone solvents that may be employed as a solvent. In certain embodiments, it has been found that acetone is a particularly useful solvent.

According to the present embodiment, the obtained fluticasone propionate in the present disclosure may be amorphous or crystalline in nature and it may be in anhydrous or hydrated crystalline form.

According to the present disclosure, fluticasone propionate may be prepared as per the prior art process disclosed in U.S. Patent No. 4,335,121. The initial particle size of fluticasone propionate employed for this disclosure is in the range of 50-75 microns.

According to the present embodiment, the obtained fluticasone propionate has a particle size d90 of less than 400microns, d50 of less than 200 microns and dlO of less than 100 microns. In a particular embodiment, the size of the particle is further micronized/sieved to get the desired particle size of d90 in the range of 307.3 microns, d50 in the range of 105.3 microns and dlO in the range of 32.7 microns.

In another embodiment of the present disclosure, the obtained fluticasone propionate particles are used for formulating the pharmaceutical composition.

The following examples are provided for illustrative purposes only and are not intended to limit the scope of the disclosure in any way.

EXPERIMENTAL SECTION:

Example-!: Preparation of crystalline Fluticasone propionate Fluticasone propionate (50gm, particle size d (90) = 50-75 micron) was dissolved in an acetone (1225ml) solvent at 25-30°C. The mixture was heated to 35-45°C and maintained for 30 minutes to get a clear solution. The clear solution was filtered through the (0.45 micron) filter paper. The temperature was raised to 50-60°C. To the above clear solution, water (562.5 ml) was added at 50-60°C over a period of 60 to 105 minutes with controlled rate, and the reaction mass was stirred for 15 - 30min. The reaction mass was cooled to an ambient temperature of 24-30°C and stirred for 14-15 hours. The reaction mass was cooled to-5°C-10°G gradually and further "stirred Tor I hour to get solid. The obtained solid is filtered and washed with an acetone/water mixture (21.75ml; 15ml of acetone mixed with 6.75ml of water). The compound is dried under the vacuum and sieved to get crystalline fluticasone propionate. Wt: 45gms Particle size:-d( 10) = 32.7 micron. d(50)= 105.3 micron. d( 90) = 307.3 micron.

We claim:

1) An improved process for the preparation of fluticasone propionate comprising the steps of:
a) dissolving fluticasone propionate in a ketone solvent to produce a mixture,
b) heating the mixture slowly for 1-2 hours to get a clear solution,
c) adding water to the step (b) solution at 50-60°C,
d) cooling to -5°C to 10°C, and
e) isolating fluticasone propionate.

2) The process according to claim 1, wherein the ketone solvent is selected from the group consisting of acetone, butanone, methyl isobutyl ketone, methyl ethyl ketone, methyl tertiary butyl ketone, and mixtures thereof.

3) The process according to claim 1, wherein the obtained fluticasone propionate has a particle size d90 of less than 400 microns, d50 of less than 200 microns and dlO of less than 100 microns.

4) The process according to claim 3, wherein the obtained fluticasone propionate has a particle size of d90 in the range of 307.3 microns, d50 in the range of 105.3 microns and dlO in the range of 32.7 microns.

Documents

Application Documents

# Name Date
1 572-CHE-2014 CORRESPONDENCE OTHERS 07-02-2014.pdf 2014-02-07
2 572-CHE-2014 FORM-3 07-02-2014.pdf 2014-02-07
3 572-CHE-2014 FORM-2 07-02-2014.pdf 2014-02-07
4 572-CHE-2014 FORM-1 07-02-2014.pdf 2014-02-07
5 572-CHE-2014 DESCRIPTION (PROVISIONAL) 07-02-2014.pdf 2014-02-07
6 572-CHE-2014 FORM-1 18-03-2014.pdf 2014-03-18
7 572-CHE-2014 CORRESPONDENCE OTHERS 18-03-2014.pdf 2014-03-18
8 572-CHE-2014 FORM-5 04-02-2015.pdf 2015-02-04
9 572-CHE-2014 FORM-2 04-02-2015.pdf 2015-02-04
10 572-CHE-2014 DESCRIPTION(COMPLETE) 04-02-2015.pdf 2015-02-04
11 572-CHE-2014 CORRESPONDENCE OTHERS 04-02-2015.pdf 2015-02-04
12 572-CHE-2014 CLAIMS 04-02-2015.pdf 2015-02-04
13 572-CHE-2014 ABSTRACT 04-02-2015.pdf 2015-02-04
14 Request for Cerfified Copy.pdf 2015-03-13
15 Petition Under Rule 137 [01-10-2015(online)].pdf 2015-10-01
16 572-CHE-2014-Form 3-181215.pdf 2016-06-13
17 Form 18 [19-05-2017(online)].pdf 2017-05-19
18 572-CHE-2014-FORM 3 [17-07-2017(online)].pdf 2017-07-17
19 572-CHE-2014-FORM 3 [01-02-2018(online)].pdf 2018-02-01
20 572-CHE-2014-FER.pdf 2019-01-04
21 572-CHE-2014-FER_SER_REPLY [18-06-2019(online)].pdf 2019-06-18
22 Marked Up Claims_Granted 316749_25-07-2019.pdf 2019-07-25
23 Description_Granted 316749_25-07-2019.pdf 2019-07-25
24 Claims_Granted 316749_25-07-2019.pdf 2019-07-25
25 Abstract_Granted 316749_25-07-2019.pdf 2019-07-25
26 572-CHE-2014-PatentCertificate25-07-2019.pdf 2019-07-25
27 572-CHE-2014-IntimationOfGrant25-07-2019.pdf 2019-07-25
28 572-CHE-2014-RELEVANT DOCUMENTS [30-03-2020(online)].pdf 2020-03-30
29 572-CHE-2014-RELEVANT DOCUMENTS [07-05-2021(online)].pdf 2021-05-07
30 572-CHE-2014-Request for Certified Copy_15-07-2021.pdf 2021-07-15
31 572-CHE-2014-RELEVANT DOCUMENTS [08-08-2022(online)].pdf 2022-08-08
32 572-CHE-2014-RELEVANT DOCUMENTS [20-09-2023(online)].pdf 2023-09-20

Search Strategy

1 572CHE2014SEARCH_03-01-2019.pdf

ERegister / Renewals

3rd: 30 Jul 2019

From 07/02/2016 - To 07/02/2017

4th: 30 Jul 2019

From 07/02/2017 - To 07/02/2018

5th: 30 Jul 2019

From 07/02/2018 - To 07/02/2019

6th: 30 Jul 2019

From 07/02/2019 - To 07/02/2020

7th: 29 Jan 2020

From 07/02/2020 - To 07/02/2021

8th: 01 Feb 2021

From 07/02/2021 - To 07/02/2022

9th: 24 Jan 2022

From 07/02/2022 - To 07/02/2023

10th: 25 Jan 2023

From 07/02/2023 - To 07/02/2024

11th: 31 Jan 2024

From 07/02/2024 - To 07/02/2025

12th: 28 Jan 2025

From 07/02/2025 - To 07/02/2026